OR WAIT 15 SECS
announced today that its Clinical Technologies division has moved into the Almac Group’s new North American Headquarters. After groundbreaking of the 40-acre site in Souderton, PA on Juy 23, 2008, the drug development firm has now completed the first phase of relocating employees from three Almac business units to the new 240,000 square feet state-of-the-art integrated drug development facility.
On October 11, Almac’s technology business unit joined employees from Almac’s analytical testing and clinical supplies units as occupants at the North American Headquarters. Over the course of the next two months, Almac will transition the remainder of its clinical supplies operations currently located in Audubon, PA, into the integrated drug development facility in Souderton, PA.
The transition of the technologies business into Almac’s new North American Headquarters was carefully planned and executed. Over the course of the past few months, Almac successfully relocated and tested all of its new and existing technologies and systems in the new locale to make certain that there were no disruptions to client studies during the transition into the North American Headquarters.
Jim Murphy, President of Almac’s clinical technologies business unit, comments on the move of the business from Yardley, PA, to its new location in Souderton, PA. Murphy: “Our IT, Quality Assurance, senior management team, and other key personnel worked in unison to ensure that all of our systems were tested and met the highest standards before we moved into the new facility. The transition team’s meticulous planning enabled us to avoid any downtime on client studies outside of our normal maintenance windows.”
The move of three Almac business units to a new North American Headquarters is part of the Almac Group’s integrated services solutions strategy. The new facility was planned to deliver a full-service, integrated drug supply management and technology solution to biopharmaceutical clients.